Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 7/20 | 0.76 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 4/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL654387 | 1.00 | CCR1 (0.76) | CCR1CHRM2CCR5OPRM1TP53 | |
| SCHEMBL10288240 | 0.90 | CCR1 (0.81) | CCR1CHRM2CCR5OPRM1TP53 | |
| SCHEMBL10288262 | 0.90 | CCR1 (0.81) | CCR1CHRM2CCR5OPRM1TP53 | |
| SCHEMBL656030 | 0.90 | CCR1 (0.78) | CCR1CHRM2CCR5TP53MDM2 | |
| SCHEMBL656029 | 0.90 | CCR1 (0.78) | CCR1CHRM2CCR5TP53MDM2 | |
| SCHEMBL653770 | 0.90 | CCR1 (0.78) | CCR1CHRM2CCR5TP53MDM2 | |
| SCHEMBL653771 | 0.90 | CCR1 (0.78) | CCR1CHRM2CCR5TP53MDM2 | |
| SCHEMBL654424 | 0.89 | CCR1 (0.79) | CCR1CHRM2CCR5TP53MDM2 | |
| SCHEMBL654425 | 0.89 | CCR1 (0.79) | CCR1CHRM2CCR5TP53MDM2 | |
| SCHEMBL654595 | 0.89 | CCR1 (0.68) | CCR1CHRM2CCR5HRH1ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | ACKR3, CCL11, CCR7 | CCR1 10/4885CHRM2 1772/4885CCR5 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.